Development of supraguard ETT, a next generation composite endotracheal tube for the prevention of ventilator-associated pneumonia

Ended Project Grant Awarded Last action

Award ID
R43HL156363
Recipient
Awarding agency
Obligated
$225,135

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Place of performance
Spokane, WA 99202, USA

Award details come from USAspending.gov.

Description

Abstract
Abstract the centers for disease control and prevention (CDC) reports that preventing ventilator associated pneumonia (VAP), as opposed to treating the acquired infection, is a critical and unmet need. To respond to this need, iasis molecular sciences will leverage strong preliminary data obtained for proprietary antimicrobial compositions (COMPOSITES). Excellent antimicrobial performance and material cytocompatibility could be beneficial in the creation of a next generation endotracheal tube that could substantively reduce VAP. Supraguardtm ETT is an advanced device wholly constructed from an antimicrobial composite designed to kill microorganisms known to cause VAP. The compositions are effective against organisms intraluminally or those located in subglottic fluids that have pooled above the cuff while maintaining excellent mechanical characteristics. The proposed research will address ETT composite formulation, composite processing, microbial inactivation, composite biocompatibility and stability, and ETT cuff viability. The major specific aims of the proposed research include: 1.) finalizing supraguardtm next generation antimicrobial endotracheal tube & cuff materials development, 2.) measure the antibacterial & antifungal effectiveness of the supraguardtm COMPOSITES. 3.) evaluate the in vitro & in vivo biocompatibility of supraguardtm COMPOSITES. There is significant commercial potential for our product, as the antimicrobial-coated ETT component of the ETT market was valued at $1.84B in 2018 and whereby the majority of antimicrobial etts are silver-coated etts. However, there are no products today that possess effective antimicrobial ETT cuffs that can effectively kill pathogens.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Original award $225,135

Quick answers

Who received award R43HL156363?

R43HL156363 was awarded to Iasis Molecular Sciences Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2021.

How much is award R43HL156363 worth?

$225,135 has been obligated on R43HL156363.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award